The majority of participants (71.2%) were already receiving treatment with intravenous or subcutaneous Ig (41 patients), corticosteroids (8 patients with ITP), and/or other therapies (6 patients with ITP), such as anti-CD20 monoclonal antibody, anti-D immunoglobulin, immunosuppressive agents, or thrombopoietin receptor agonists. The gene discussed is MPL; the disease is autoimmune thrombocytopenic purpura.